Literature DB >> 29336436

Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.

Alberico L Catapano1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29336436     DOI： 10.1038/nrcardio.2017.221

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.

Authors:  Louise Bowman; Jemma C Hopewell; Fang Chen; Karl Wallendszus; William Stevens; Rory Collins; Stephen D Wiviott; Christopher P Cannon; Eugene Braunwald; Emily Sammons; Martin J Landray
Journal:  N Engl J Med       Date:  2017-08-28       Impact factor: 91.245

2.  Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.

Authors:  Antonio J Vallejo-Vaz; Michele Robertson; Alberico L Catapano; Gerald F Watts; John J Kastelein; Chris J Packard; Ian Ford; Kausik K Ray
Journal:  Circulation       Date:  2017-09-06       Impact factor: 29.690

3.  Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.

Authors:  Kausik K Ray; Ulf Landmesser; Lawrence A Leiter; David Kallend; Robert Dufour; Mahir Karakas; Tim Hall; Roland P T Troquay; Traci Turner; Frank L J Visseren; Peter Wijngaard; R Scott Wright; John J P Kastelein
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

4.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

5.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Authors:  Robert P Giugliano; Terje R Pedersen; Jeong-Gun Park; Gaetano M De Ferrari; Zbigniew A Gaciong; Richard Ceska; Kalman Toth; Ioanna Gouni-Berthold; Jose Lopez-Miranda; François Schiele; François Mach; Brian R Ott; Estella Kanevsky; Armando Lira Pineda; Ransi Somaratne; Scott M Wasserman; Anthony C Keech; Peter S Sever; Marc S Sabatine
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

6.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

7.  Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.

Authors:  Gergana Galabova; Sylvia Brunner; Gabriele Winsauer; Claudia Juno; Bettina Wanko; Andreas Mairhofer; Petra Lührs; Achim Schneeberger; Arne von Bonin; Frank Mattner; Walter Schmidt; Guenther Staffler
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

8.  Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis.

Authors:  Shaohua Wang; Rongrong Cai; Yang Yuan; Zac Varghese; John Moorhead; Xiong Z Ruan
Journal:  Sci Rep       Date:  2017-01-10       Impact factor: 4.379

9.  Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.

Authors:  Marianne Benn; Børge G Nordestgaard; Ruth Frikke-Schmidt; Anne Tybjærg-Hansen
Journal:  BMJ       Date:  2017-04-24

10.  The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.

Authors:  Christine Landlinger; Marianne G Pouwer; Claudia Juno; José W A van der Hoorn; Elsbet J Pieterman; J Wouter Jukema; Guenther Staffler; Hans M G Princen; Gergana Galabova
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983
  10 in total
  2 in total

1.  High-density lipoproteins may play a crucial role in COVID-19.

Authors:  Minu Nain; Apoorv Gupta; Sumit Malhotra; Amit Sharma
Journal:  Virol J       Date:  2022-08-23       Impact factor: 5.913

Review 2.  Role of cholesterol and sphingolipids in brain development and neurological diseases.

Authors:  Ghulam Hussain; Jing Wang; Azhar Rasul; Haseeb Anwar; Ali Imran; Muhammad Qasim; Shamaila Zafar; Syed Kashif Shahid Kamran; Aroona Razzaq; Nimra Aziz; Waseem Ahmad; Asghar Shabbir; Javed Iqbal; Shahid Mahmood Baig; Tao Sun
Journal:  Lipids Health Dis       Date:  2019-01-25       Impact factor: 3.876
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.